Vaxcyte Inc NASDAQ:PCVX Price, Chart, News & Insight

NASDAQ:PCVX

Vaxcyte Stock Surges 46.4% as Guggenheim Raises Price Target After Positive VAX-31 Phase 3 Data

Vaxcyte shares jumped 46.4% to $82.68 after Guggenheim raised its price target to $125 from $116 while maintaining a Buy rating.

The move followed positive topline results from the pivotal Phase 3 OPUS-1 trial of VAX-31, the company’s 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified primary endpoints across the age groups studied compared with Prevnar 20 and Capvaxive.

Among adults aged 50 and older, all 28 serotypes shared with PCV20 and/or PCV21 met the trial’s noninferiority threshold. The three serotypes unique to VAX-31, along with cross-reactive serotype 20B, met the superiority criterion. VAX-31 also met the primary immunobridging endpoint across all 321 serotype comparisons in adults aged 18 to 49.

Safety was another positive, with VAX-31 showing a profile similar to PCV20 and PCV21 and no vaccine-related serious adverse events reported.

The sharp rally reflects increased confidence that VAX-31 could become a broad-spectrum competitor in the adult pneumococcal vaccine market. Vaxcyte expects additional Phase 3 data from OPUS-2 and OPUS-3 in the first half of 2027, with a planned Biologics License Application submission in the first half of 2028.

💬

WS Investor 10-05-26

Vaxcyte, Inc. disclosed that it completed a large equity financing following the sale of 11.0 million shares at $50.00 per share, with underwriters exercising their option to purchase an additional 1.65 million shares. The offering generated approximately $600.2 million in net proceeds after underwriting discounts and expenses. The shares were sold pursuant to an effective Form S-3 registration statement, and the transaction closed on February 2, 2026.

💬

European Investor 02-03-26

Vaxcyte, Inc. (Nasdaq: PCVX) announced that on September 24, 2025, it entered into a long-term Master Services Agreement with Patheon Manufacturing Services LLC, a Thermo Fisher Scientific company, to produce its drug products at Patheon’s Greenville, North Carolina facility. Under the 15-year agreement, which automatically renews for three-year terms unless terminated, Patheon will handle formulation, filling, inspection, packaging, labeling, testing, manufacturing, and supply. Vaxcyte committed to purchasing binding minimum amounts at set prices, with adjustments possible, and will also cover technology transfer costs and reimburse certain capital expenditures.

The deal includes customary provisions such as confidentiality, warranties, and liability limits, while termination rights allow either party to end the agreement under conditions like legal violations, insolvency, or material breach. If Vaxcyte terminates for convenience, it must pay Patheon the greater of a fixed mid-eight-figure sum or amounts tied to current forecasts, plus capital commitments; termination for program failure carries separate agreed fees. The full contract will be filed with the SEC in Vaxcyte’s Q3 2025 Form 10-Q.

💬

WS Investor 09-30-25

Vaxcyte reported strong progress in its pneumococcal conjugate vaccine (PCV) programs, achieving key milestones in 2024 and preparing for major clinical advancements in 2025. The company successfully completed its VAX-31 Phase 2 adult program and is on track to initiate a Phase 3 pivotal, non-inferiority study by mid-2025, with topline safety, tolerability, and immunogenicity data expected in 2026. In the pediatric segment, Vaxcyte plans to announce Phase 2 topline data for the VAX-24 infant primary immunization series by the end of Q1 2025, followed by booster dose data at the end of the year. Additionally, the VAX-31 infant study advanced to its final stage, with primary immunization data anticipated in mid-2026.

Financially, Vaxcyte strengthened its position by raising $2.2 billion through two follow-on equity offerings in 2024, bringing its cash, cash equivalents, and investments to $3.1 billion as of December 31, 2024. This financial stability supports its clinical programs, global manufacturing readiness, and early-stage pipeline, including vaccine candidates for Group A Strep and Shigella.

Key developments include VAX-31 receiving Breakthrough Therapy Designation from the FDA for invasive pneumococcal disease (IPD) prevention in adults and positive Phase 2 results for VAX-24 in older adults, validating Vaxcyte’s carrier-sparing platform. The company also made leadership appointments to strengthen technical operations, regulatory strategy, and organizational growth.

Looking ahead, Vaxcyte will initiate multiple Phase 3 studies for VAX-31 in 2025 and 2026, with data readouts extending into 2027. It also plans to participate in investor conferences, including Cowen’s 45th Annual Health Care Conference and the Leerink Global Healthcare Conference in March 2025.

For Q4 and full-year 2024, Vaxcyte reported an increase in R&D expenses to $476.6 million, driven by expanded clinical and manufacturing activities. General and administrative expenses rose to $92.9 million, reflecting organizational growth. The company posted a net loss of $463.9 million for 2024, compared to $402.3 million in 2023. Capital expenditures for manufacturing suite construction at Lonza totaled $127.8 million in 2024, bringing total facility investment to $214.3 million.

Vaxcyte will host a webcast and conference call today at 4:30 p.m. ET to discuss its financial results and business updates.

💬

European Investor 02-26-25

NASDAQ:PCVXFollow

NASDAQ:PCVX